Kineta Announces Poster Presentation at American Association for Cancer Research 2021 Immunology and Tumor Immunotherapy Conference | State

SEATTLE, September 28, 2021 / PRNewswire / – Kineta, Inc., a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, today announced that it will present a poster on the new anti-CD27 agonist antibody program of the company at the American Association for Cancer Research (AACR) Virtual Special Conference: Tumor Immunology and Immunotherapy, to be held on October 5-6, 2021.

Title: A promising target for cancer immunotherapy: new fully human agonist antibodies directed against the human CD27 T cell costimulatory receptor

Date poster available: October 5, 2021

Kineta is a clinical-stage biotechnology company whose mission is to develop next-generation immunotherapies that transform patients’ lives. We have leveraged our expertise in innate immunity to develop world-class or best-in-class immunotherapies that address the main challenges of current cancer therapies. For more information about Kineta, visit our website,, and follow us on Twitter, LinkedIn and Facebook.

NOTICE: This document contains certain forward-looking statements, including, without limitation, statements regarding Kineta’s plans for preclinical and clinical studies, regulatory filings, investor feedback, and the expected effects of the drugs in human subjects. . You are cautioned that these forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business that could significantly affect expected results, including, but not limited to, the progress of the Company. drug development, the ability to raise capital to fund drug development, clinical trials and regulatory approval, changes in raw material and personnel costs, and legislative, tax and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta assumes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the issuance of this press release.


Jacques Bouchy

[email protected]

(206) 378-0400

View original content to download multimedia: -tumor -immunology-and-immunotherapy-301386647.html

SOURCE Kinéta, Inc.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *